The HIV prevention cascade: more smoke than thunder?

The Lancet HIV

Volumn 3, Issue 7, 2016, Pages e286-e288

  Godfrey Faussett, Peter ^a,b  

^a UNAIDS   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; ASIA; CONDOM USE; EUROPE; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HELP SEEKING BEHAVIOR; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MEN WHO HAVE SEX WITH MEN; NONHUMAN; NOTE; PATIENT ADVOCACY; PRE-EXPOSURE PROPHYLAXIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; UNITED NATIONS; AFRICA SOUTH OF THE SAHARA; EPIDEMIOLOGY; FEMALE; HEALTH CARE DELIVERY; HOMOSEXUALITY; MORTALITY;

AFRICA SOUTH OF THE SAHARA; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HOMOSEXUALITY; HUMANS;

EID: 84991716235     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(16)30062-5     Document Type: Note

References (20)

1. 1 UNAIDS. Global AIDS Update. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf, 2016 (accessed June 10, 2016).
2. 2 Dehne, KL, Dallabetta, G, Wilson, D, et al. HIV Prevention 2020: a framework for delivery and a call for action. Lancet HIV 3 (2016), e323–e332.
3. 3 UNAIDS. 90–90–90 — an ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/en/resources/documents/2014/90-90-90 (accessed June 11, 2016).
4. 4 INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
5. 5 TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 373 (2015), 808–822.
6. 6 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://www.who.int/hiv/pub/arv/arv-2016/en/ (accessed June 11, 2016).
7. 7 Krishnaratne, S, Hensen, B, Cordes, J, Enstone, J, Hargreaves, JR, Interventions to strengthen the HIV prevention cascade: a systematic review of reviews. Lancet HIV 3 (2016), e307–e317.
8. 8 Hargreaves, JR, Delany-Moretlwe, S, Hallett, TB, et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. Lancet HIV 3 (2016), e318–e322.
9. 9 Garnett, GP, Hallett, TB, Takaruza, A, et al. Providing a conceptual framework for HIV prevention cascades and assessing feasibility of empirical measurement with data from east Zimbabwe: a case study. Lancet HIV 3 (2016), e297–e306.
10. 10 Waaler, H, Piot, M, The use of an epidemiological model for estimating the effectiveness of tuberculosis control measures. Bull World Health Organ 41 (1969), 75–93.
11. 11 Hayes, R, Wawer, M, Gray, R, Whitworth, J, Grosskurth, H, Mabey, D, Randomised trials of STD treatment for HIV prevention: report of an international workshop. HIV/STD Trials Workshop Group. Genitourin Med 73 (1997), 432–443.
12. 12 Mumba, M, Visschedijk, J, van Cleeff, M, Hausman, B, A Piot model to analyse case management in malaria control programmes. Trop Med Int Health 8 (2003), 544–551.
13. 13 UNAIDS. Fast-tracking combination prevention. http://www.unaids.org/sites/default/files/media_asset/20151019_JC2766_Fast-tracking_combination_prevention.pdf (accessed June 11, 2016).
14. 14 Bauer, GR, Travers, R, Scanlon, K, Coleman, TA, High heterogeneity of HIV-related sexual risk among transgender people in Ontario, Canada: a province-wide respondent-driven sampling survey. BMC Public Health, 12, 2012, 292.
15. 15 Smith, JA, Anderson, S-J, Harris, KL, et al. Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study. Lancet HIV 3 (2016), e289–e296.
16. 16 Namey, E, Agot, K, Ahmed, K, et al. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health Sex, 2016, 10.1080/13691058.2016.1164899 published online April 19.
17. 17 Ferrer, L, Loureiro, E, Meulbroek, M, et al. High HIV incidence among men who have sex with men attending a community-based voluntary counselling and testing service in Barcelona, Spain: results from the ITACA cohort. Sex Transm Infect 92 (2016), 70–75.
18. 18 McCormack, S, Dunn, DT, Desai, M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387 (2016), 53–60.
19. 19 De Neve, JW, Fink, G, Subramanian, SV, et al. Length of secondary schooling and risk of HIV infection in Botswana: evidence from a natural experiment. Lancet Glob Health 3 (2015), e470–e477.
20. 20 Kim, JY, Rhatigan, J, Jain, SH, Weintraub, R, Porter, ME, From a declaration of values to the creation of value in global health: a report from Harvard University's Global Health Delivery Project. Glob Public Health 5 (2010), 181–188.